Skip to main content
OpenTrials
Completed

NCT Number: NCT02999256

Effect of Cherry Juice on Fat Oxidation and Cardio-metabolic Markers

The present study examined the effect of Montmorency tart cherry juice and FATMAX (intensity eliciting maximal fat oxidation) exercise on fat oxidation rates, body composition and blood-based cardio-metabolic markers. Participants received both Montmorency tart cherry juice and placebo in a random counterbalanced order for 20 days. Outcome variables were measured immediately pre- and post-supplementation and 10 days after the onset of supplementation. It was hypothesised that Montmorency tart cherry juice would increase fat oxidation during exercise, reduce body fat percentage and improve cardio-metabolic markers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Aims: (1) Examine whether tart cherry juice supplementation with cycling exercise augments fat oxidation rate and therefore plays a role in weight management in healthy active human participants. (2) To extrapolate findings from this study to future biomedical health and disease research.

Methods: Random counterbalanced, within-group, double-blind study design. Participants were randomly allocated into consuming either cherry juice first or placebo. Eleven recreationally active male and female participants were recruited. Participants consumed 30ml Montmorency tart cherry juice concentrate mixed with 100ml water, twice daily for 20 days. Participants underwent a 14 day washout period between trials. All participants were instructed to keep to their habitual intake of polyphenols and anthocyanins. Twenty-four hours before each exercise testing session, participants consumed similar meals at the same times. Diet adherence was monitored through food diaries.

Participants attended each testing session following an overnight fast, with the testing being completed at the same time in the morning to avoid circadian variation. Preliminary testing was conducted to ascertain VO2max and individual FATMAX, 4 days before the one hour pre-supplementation exercise test. VO2max was re-assessed 4 days before the one hour post-supplementation exercise test to determine if any changes in training status affected results.

Testing will occur at baseline, 10 days after the onset of supplementation and after 20 days supplementation. Exercise protocol consisted of 60min cycling at pre-determined individual FATMAX. Continuous gas analysis and heart rate were monitored throughout. Substrate oxidation rates and energy expenditure were calculated using stoichiometric equations (Jeukendrup and Wallis, 2005). During each testing session blood pressure and body composition (impedance) measurements were taken at baseline and pre-exercise during all testing sessions. Resting metabolic rate (indirect calorimetry) was assessed at baseline and pre-exercise during all testing sessions.

Serum blood samples were obtained from participants at the following time points: baseline, pre-exercise and post-exercise for one hour submaximal exercise tests, in both trials. The following markers were analysed: Glucose, Lactate, Triglycerides, HDL, Total Cholesterol and Total Antioxidant Status.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18-45
  • Male and Female
  • Non-smokers
  • Recreationally active (minimum 150 minutes physical activity per week)
  • Injury free at all times of testing.

Exclusion criteria

  • Aged <18 years old, >45 years old
  • Current or previous history of gastrointestinal, cardiovascular or renal disease
  • Current or previous history of injury that may be exacerbated with the exercise protocol used
  • Allergy to maltodextrin or specific fruit products (especially cherries) and those currently taking medication (such as steroids, NSAIDs, antibiotics) or currently using any nutritional supplement.

Treatment and study plan

Montmorency Tart Cherry Juice

Dietary Supplement

Placebo

Other

Primary outcomes

  1. Change in Fat Oxidation (grams/min)

    Time frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms

Secondary outcomes

  1. Change in Lipid Profile (Total Cholesterol, HDL, Triglycerides, LDL) (mmol/L)

    Time frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms

  2. Change in Serum Glucose (mmol/L)

    Time frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms

  3. Change in Body Fat Percentage (%)

    Time frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms

  4. Change in Body Mass (kg)

    Time frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms

  5. Change in Fat Mass (kg)

    Time frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms

  6. Change in Fat Free Mass (kg)

    Time frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms

  7. Change in Total Antioxidant Status (mmol/L)

    Time frame: Pre-, Mid- (10 days) and Post- (21 days) after onset of Supplementation in both Arms

Sponsors and collaborators

Lead sponsor

University of Hertfordshire

Other

Registry information

Official study title

The Effect of Tart Cherry Juice Supplementation on Fat Oxidation, Body Composition and Cardio-Metabolic Markers With Cycling Exercise

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Dec 21, 2016
Registry last updated
Dec 21, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.